Brief: Ayala Pharmaceuticals Announces Successful End-Of-Phase 2 Meeting With FDA Regarding Al102 For The Treatment Of Desmoid Tumors
05/07/2023 13:29
July 5 (Reuters) - Ayala Pharmaceuticals Inc ADXS.PK :
* AYALA PHARMACEUTICALS ANNOUNCES SUCCESSFUL END-OF-PHASE 2
MEETING WITH FDA REGARDING AL102 FOR THE TREATMENT OF DESMOID
TUMORS
* AYALA PHARMACEUTICALS INC: ENROLLMENT IN PHASE 3 SEGMENT
OF
RINGSIDE COMMENCED IN NOVEMBER 2022, AND IS CONTINUING GLOBALLY
AS PLANNED
Source text for Eikon: ID:nGNX95VgYp
Further company coverage: ADXS.PK
((reuters.briefs@thomsonreuters.com;))
Recent news on Ayala Pharmaceuticals
See all newsBrief: Ayala Pharmaceuticals Completes Sale Of AL102 To Immunome
Immunome slides on $200 mln equity offering
Immunome edges up after $200 mln equity offering
Brief: Immunome To Acquire AL102 Phase 3 Asset for the Treatment of Desmoid Tumors From Ayala Pharmaceuticals
Brief: Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors